Near tetraploid prostate carcinoma: Methodologic and prognostic aspects

Cancer

Volumn 78, Issue 8, 1996, Pages 1748-1755

  Forsslund, Gun ^a   Nilsson, Bo ^b   Zetterberg, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

DNA ploidy; hormonal treatment; image cytometry; prognosis; prostate carcinoma; tetraploid tumors

Indexed keywords

DNA; ESTROGEN;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIPLOIDY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ORCHIECTOMY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; TETRAPLOIDY;

CARCINOMA; DNA, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; IMAGE CYTOMETRY; MALE; PLOIDIES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0029759894     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961015)78:8<1748::AID-CNCR15>3.0.CO;2-Y     Document Type: Article

References (25)

1. Forsslund G, Zetterberg A. A quantitative evaluation of cytophotometric DNA-analysis in retrospective studies using archival tumor specimens. Anal Quant Cytol Histol 1990;12:259-66.
2. Zetterberg A, Esposti PL. Prognostic significance of nuclear DNA level in prostatic carcinoma. Scand J Urol Nephrol 1980;55:53-8.
3. Eneroth CM, Zetterberg A. The relationship between the nuclear DNA content in smears of aspirates and the prognosis of mucoepidermoid carcinoma. Acta Otolaryngol (Stockh) 1975;80:429-33.
4. Forsslund G, Esposti P, Nilsson B, Zetterberg A. The prognostic significance of nuclear DNA content in prostatic carcinoma. Cancer 1992;69(6):1432-9.
5. Zetterberg A, Esposti PL. Cytophotometric DNA-analysis of aspirated cells from prostatic carcinoma. Acta Cytol 1976;20:46-57.
6. Forsslund G, Zetterberg A. Ploidy level determinations in high-grade and low-grade malignant variants of prostatic carcinoma. Cancer Res 1990;50(14):4281-5.
7. Fordham MV, Burdge AH, Matthews J, Williams G, Cooke T. Prostatic carcinoma cell DNA content measured by flow cytometry and its relation to clinical outcome. Br J Surg 1986;73:400-3.
8. Haugen OA, Mjolnerod O. DNA ploidy as a prognostic factor in prostatic carcinoma. Int J Cancer 1991;45:224-8.
9. Humphrey PA, Walther PJ, Currin SM, Vollmer RT. Histologic grade, DNA ploidy and intraglandular tumor extent as indicators of tumor progression of clinical stage B prostatic carcinoma. A direct comparison. Am J Surg Pathol 1991;15:1165-70.
10. Lee SE, Currin SM, Paulson DF, Walther PJ. Flow cytometric determination of ploidy in prostatic carcinoma: a comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. J Urol 1988;140:769-74.
11. Mohler JL, Platin AW, Epstein JI, Becker RL, Michael UV, Sesterhenn IA, et al. Prediction of prognosis in untreated stage A2 prostatic carcinoma. Cancer 1992;69:511-9.
12. Montgomery BT, Nativ O, Blute ML, Farrow GM, Myers RP, Zincke H, et al. Stage B prostate adenocarcinoma. Flow cytometric nuclear DNA ploidy analysis. Arch Surg 1990; 125:327-31.
13. Esposti PL. Cytologic malignancy grading of prostatic carcinoma by transrectal aspiration biopsy. ScandJ Urol Nephrol 1971;5:199-209.
14. Hermanek P, Sobin LH, editors. International Union Against Cancer. TNM Classification of malignant tumours. Berlin: Springer-Verlag, 1987:124-6.
15. Decosse JJ, Elello N. Feulgen hydrolysis: effect of acid and temperature J Histochem Cytochem 1966;14:601-4.
16. Eneroth CM, Zetterberg A. Microspectrophotometric DNA analysis of malignant salivary gland tumors. Acta Otolaryngol (Stockholm) 1974;77:289-94.
17. Forsslund G, Kreicbergs A, Nilsson B, Zetterberg A. Photographic densitometry for quantitative DNA analysis of cytological and histological pecimens. Anal Quant Cytol Histol 1992;153-60.
18. Eneroth CM, Zetterbeg A. A cytochemical method of grading the malignancy of salivary gland tumors preoperatively. Acta Otolaryngol (Stockholm) 1976;81:489-95.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
20. Cox DR. Regression model and life tables (with discussion). JR Stat Soc B 1972;234:187-220.
21. Shankey V, Kallioniemi O, Koslowski J, Lieber M, Mayall B, Miller G, et al. Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry 1993;14:497-500.
22. Zincke H, Bergstralh EJ, Larsson-Keller JJ, Farrow GM, Myers RP, Lieber MM, et al. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survival in patients with DNA diploid tumors. Cancer 1992;70(Suppl 1):311-23.
23. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method to analysis of cellular DNA content paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333-5.
24. Askensten UG, Moberger B, Auer GU. Methodological aspects on cytochemical DNA assessments of adenocarcinoma in the endometrium by means of image and flow cytometry using conventionally formalin fixed and paraffin-embedded specimens. Archiv für Geschwust forschung 1990;60:209-16.
25. Latham C, Månér S, Biegen H, Eriksson E, Zickert P, Auer G, et al. Relationship between oncogene amplification, aneuploidy and altered expression of p53 in breast cancer. Int J Oncol 1996;8:359-65.